- Home
- FATE vs AGEN Comparison
FATE vs AGEN Comparison
Compare FATE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- AGEN
- Stock Information
- Founded
- FATE 2007
- AGEN 1994
- Country
- FATE United States
- AGEN United States
- Employees
- FATE N/A
- AGEN N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FATE Health Care
- AGEN Health Care
- Exchange
- FATE Nasdaq
- AGEN Nasdaq
- Market Cap
- FATE 108.2M
- AGEN 38.1M
- IPO Year
- FATE 2013
- AGEN 2000
- Fundamental
- Price
- FATE $0.77
- AGEN $1.63
- Analyst Decision
- FATE Hold
- AGEN Buy
- Analyst Count
- FATE 9
- AGEN 4
- Target Price
- FATE $5.50
- AGEN $8.00
- AVG Volume (30 Days)
- FATE 1.6M
- AGEN 503.8K
- Earning Date
- FATE 03-05-2025
- AGEN 05-06-2025
- Dividend Yield
- FATE N/A
- AGEN N/A
- EPS Growth
- FATE N/A
- AGEN N/A
- EPS
- FATE N/A
- AGEN N/A
- Revenue
- FATE $13,631,000.00
- AGEN $103,463,000.00
- Revenue This Year
- FATE N/A
- AGEN $4.03
- Revenue Next Year
- FATE N/A
- AGEN $5.57
- P/E Ratio
- FATE N/A
- AGEN N/A
- Revenue Growth
- FATE N/A
- AGEN N/A
- 52 Week Low
- FATE $0.74
- AGEN $1.44
- 52 Week High
- FATE $7.35
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- FATE 33.08
- AGEN 30.04
- Support Level
- FATE $0.83
- AGEN $1.44
- Resistance Level
- FATE $0.96
- AGEN $1.77
- Average True Range (ATR)
- FATE 0.06
- AGEN 0.13
- MACD
- FATE -0.00
- AGEN 0.04
- Stochastic Oscillator
- FATE 11.54
- AGEN 38.78
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).